Epicardial fat thickness in children with CAH

Sayed, Samira Zain; Abdelaziz, Ghada Sayed; Setohi Abdelhafez, Amr Mostafa; ElBakry, Noura Mohammed

doi:10.21608/mjmr.2025.417467.2089

Epicardial fat thickness in children with CAH

Articles in Press

Document Type : Original Article

Authors

¹ Professor of Pediatrics, Faculty of Medicine, Minia University

² MBBCH, Faculty of Medicine, Minia University

³ cardiology department ,faculty of medicine ,minia university

⁴ Pediatric Department, Faculty of Medicine, Minya University, Egypt

10.21608/mjmr.2025.417467.2089

Abstract

Background: Congenital adrenal hyperplasia (CAH) was an autosomal recessive disorder originating from abnormalities in enzymes necessary for adrenal steroid production. 21-hydroxylase deficiency was predominant enzymatic abnormality responsible for (CAH). 21-hydroxylase deficiency may adversely impact vascular architecture & cardiac systolic & diastolic function.

Aim: To evaluate cardiovascular consequences in pediatric cases with congenital adrenal hyperplasia. On long term of steroid therapy

Patients and methods: This comparative cross-sectional case-control study comprised 40 children: 20 children diagnosed with classic CAH (case group). Assessments indicated increased concentrations of adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), testosterone, alongside diminished morning & evening cortisol levels. (SW) variant was recognized in cases with significant hyponatremia & hyperkalemia. & twenty age- & sex-matched healthy children (control group).

Inclusion Criteria: All children with CAH, aged from 1-16 years and starting the period of our study from October 2024, on treatment for at least 6 months, treated at a single tertiary hospital and written consent and Permission from the father or the mother.

Exclusion criteria: children with comorbidities as renal diseases that may affect blood pressure measurement or cardiac output, children diagnosed with other congenital heart diseases that may affect blood pressure measurement or cardiac output and newly diagnosed patient (less than 6 months), patient on any treatment that may affect cardiovascular system except hydrocortisone & mineralocorticoid and poor control or poor compliance for CAH _ hormonal therapy _ ( last 17-OH progesterone serum level was above 10ng/dl ) or manifested by electrolyte imbalance or high ACTH serum level or low cortisol

Keywords

Main Subjects